BeOne Medicines (NASDAQ:ONC) & PainReform (NASDAQ:PRFX) Critical Review

PainReform (NASDAQ:PRFX) and BeOne Medicines (NASDAQ:ONC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

37.3% of PainReform shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares PainReform and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
BeOne Medicines	10.70%	14.23%	7.82%

Volatility & Risk

PainReform has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PainReform and BeOne Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
BeOne Medicines	0	2	13	2	3.00

BeOne Medicines has a consensus price target of $404.93, suggesting a potential upside of 16.00%. Given BeOne Medicines’ stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than PainReform.

Valuation and Earnings

This table compares PainReform and BeOne Medicines”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	35.58	-$5.02 million	($736.66)	-0.00
BeOne Medicines	$5.34 billion	7.17	$286.93 million	$5.68	61.46

BeOne Medicines has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats PainReform on 12 of the 15 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.